XOMA
XOMA Royalty Corp is a royalty aggregator that acquires economic rights to milestone and royalty payments from over 120 clinical candidates and approved products across multiple therapeutic areas including oncology, rare disease, women's health, retinal diseases, and neonatology, with drug modalities spanning monoclonal antibodies, bispecific antibodies, gene therapy, small molecules, and protein therapeutics. The company's portfolio includes seven commercial-stage assets generating $33.6 million in royalties during 2025, anchored by products such as Vabysmo (faricimab-svoa), a bispecific antibody for retinal diseases; Ojemda (tovorafenib), a pan-RAF inhibitor for pediatric oncology; and Miplyffa (arimoclomol), a heat-shock protein modulator for rare disease, along with 14 late-stage clinical candidates